ash 2022: relapsed/refractory aml - results from the randomized phase iii asap trial
Published 1 year ago • 462 plays • Length 6:31Download video MP4
Download video MP3
Similar videos
-
10:02
ash 2022: talquetamab in patients with relapsed/refractory multiple myeloma (rrmm): phase 1/2 re...
-
6:30
phase iii asap trial results: role of remission induction chemotherapy before allohct in r/r aml
-
3:21
ash 2022 lba: results from the ecog-acrin e1910 trial
-
29:35
what time is the right time for transplantation?
-
6:44
ash 2020: highlights for patients with relapsed/refractory aml
-
7:36
alexander perl, eha 2019 – the phase iii admiral trial
-
52:20
acute myeloid leukemia: incorporating novel treatment approaches into clinical pathways
-
0:39
aml clinical trials: early stage vs. relapse/refractory patients
-
3:14
ash 22 | myeloma xi clinical trial
-
3:41
preliminary results from phase i study of cd123 car-t therapy in pediatric r/r aml
-
7:57
eha22: 10-day decitabine vs. conventional chemotherapy (“3 7”) followed by allografting (hsct) i...
-
2:09
updates from the phase iii lacewing trial
-
5:52
eytan m. stein, md: enasidenib shows "encouraging" efficacy in idh2-mutated aml
-
1:04:24
yale ash 2022 highlights: myeloid leukemia
-
1:04:53
acute myeloid leukemia (aml): finally making progress? j. zeidner - 20180523
-
1:33
phase i trial results for oral azacitidine and venetoclax in r/r aml
-
1:48
idh1 inhibitor ivosidenib for the treatment of relapsed/ refractory aml
-
1:33
what effect does gilteritinib have on flt3 mutated relapsed/refractory aml?
-
1:12
hma in combination with venetoclax and magrolimab in the treatment of aml